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Recent EACVI recommendations described the importance of limiting cardiovascular 
imaging during the COVID-19 pandemic in order to reduce virus transmission, protect 
health care professionals from contamination and reduce personal protective 
equipment consumption. However, an elevated troponin remains a frequent request for 
cardiac imaging in COVID-19 patients, partly because it signifies cardiac injury due to a 
variety of causes and partly because it is known to convey a worse prognosis. The 
present paper aims to provide guidance to clinicians regarding the appropriateness of 
cardiac imaging in the context of troponin elevation and myocardial injury, how best to 






The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the pathogen 
responsible for the pandemic disease, « coronavirus disease 2019 » or « COVID-19 », 
resulting in important morbidity and mortality all around the world. The risk of 
fatalities has been shown to be increased by 15% in patients with a previous history of 
cardiovascular disease (CVD) and/or with CVD risk factors.1,2 Additionally, an increase 
in troponin above the 99th percentile upper reference limit during the course of COVID 
19, suggesting cardiac injury, is associated with higher risk of in-hospital mortality.3 In 
many countries, the risk of overwhelmed critical care capacity has led to the need to 
better stratify patient risk and to thereby determine who would benefit most from 
required intensive therapy and conversely those patients best treated conservatively. 
The interpretation of elevated cardiac troponin levels in COVID-19 is challenging 
because it may be due to a wide range of cardiac insults, occurring at various stages of 
the disease, with variable implications for prognosis and clinical decision-making. As a 
consequence, complementary imaging examinations are frequently requested in order 
to clarify the diagnosis and prognosis of these patients. Such imaging requests need to 
be carefully considered in light of the recent EACVI recommendations on cardiovascular 
imaging during the COVID-19 pandemic. These insisted upon limiting cardiac imaging in 
COVID-19 patients to only those situation where « it is likely to substantially change 
patient management or be lifesaving »,4 in order to reduce virus transmission, protect 
heath care professionals from contamination and limit personal protective equipment 
(PPE) consumption. The aim of the present paper is to provide guidance to clinicians 
regarding the appropriateness of cardiac imaging in COVID-19 patients with suspected 
or established myocardial injury, and how cardiac imaging has the potential to influence 
therapy. 
 




Myocardial injury in the context of COVID-19 is usually defined as an increase of 
troponin above the 99th percentile of the upper reference limit during the course of the 
disease. It is difficult to define absolute threshold values due to local variations in the 
methods used in the different laboratories, and in the context of some clinical conditions 
 4 
(i.e. chronic renal failure). The interpretation of increased troponin requires careful 
integration with a range of other clinical factors (symptoms, history of CVD and other 
co-morbidities, ECG changes etc.). The amplitude of the troponin increase as well as its 
dynamic nature (e.g. an acute rise and fall vs more persistent elevations) and 
comparison with historical measurements may also be informative. A mild increase in 
troponins is often found in patients with COVID-19 and pre-existing cardiac disease.5 
This multiparametric approach will inform indications for cardiac imaging. (Fig.1) 
 
2.2 Prevalence of myocardial injury 
 
The prevalence of myocardial injury in COVID-19 is estimated to be between 23-28 % 
but it is difficult to be precise as evidence is based only on previous reports from China, 
which have limitations. According to these reports troponin levels were not available in 
25-32% of these patients and were probably an overestimate given the potential 
selection bias as troponin levels were probably requested in those who were more 
critical unwell or in cases where myocardial ischaemia or myocardial dysfunction was 
suspected. Patients with high troponin levels showed higher incidence of complications 
such as acute respiratory syndrome, malignant arrhythmias, acute renal injury, and 
acute coagulopathy. The presence of both CVD and elevated troponin was associated 
with the highest mortality rate while patients without elevated troponin levels, even in 




In addition to classic acute coronary syndromes (ACS) and other commonly encountered 
conditions such as myocarditis, takotsubo cardiomyopathy, and cardiac dysrhythmia, 
four putative and direct mechanisms of acute cardiac injury due to COVID-19 have been 
proposed. First, viral ACE-2 mediated direct damage. Second, hypoxia-induced 
myocardial injury. Third, cardiac microvascular damage due to perfusion defects, vessel 
hyperpermeability or angiospasm, and fourth, systemic inflammatory response 
syndrome including cytokines storm, dysregulated immunocytes and uncontrolled 





Myocardial injury could be multifactorial and may occur at different phases of the 
COVID-19 disease, even late after the onset of symptoms.9(Fig.2) In most series, 
myocardial injury occurs around seven days after the onset of symptoms. Depending on 
the clinical context, the suspected mechanisms, the timing and the potential 
management implications, the most efficient imaging modality should be selected. Table 
1 summarizes the potential roles of the various imaging modalities according to this 
proposed approach.  
 
3. Myocardial injury: Differential diagnoses 
 
A rise in troponin concentration may have a wide range of underlying causes other than 
ACS and may occur without significant angiographic coronary artery disease.10 The 
potential causes are summarized in Table 2. Imaging is well placed to decipher the 
mechanism of injury in COVID-19 patients and we here provide guidance to clinicians 
using different clinical scenarios regarding the indication for cardiac imaging and also 
which modality to use. 
 
3.1 Suspicion of coronary artery disease 
 
Acute and chronic coronary syndromes may occur in COVID-19 patients. First of all, high 
level of comorbidities, poor quality of life, and frailty may render additional 
examinations futile. The likelihood of coronary artery disease (CAD) based on 
symptoms, electrocardiogram (ECG), age, sex, previous history and CVD risk factors 
informing the pre-test probability have to be evaluated.11 If pre-test probability is low 
and/or an alternative explanation for the troponin release is found, further cardiac 
imaging is not required. If the suspicion for an ACS is very high and patients are deemed 
at high-risk, an invasive coronary angiogram should be proposed, especially in ST 
elevation myocardial infarction (STEMI), high-risk non-STEMI, and crescendo angina. In 
intermediate risk ACS population, a coronary computed tomography (CCT) angiography 
is recommended.11 Cardiovascular magnetic resonance (CMR) is a potential alternative. 
If obstructive CAD is present, revascularization should be discussed, although this may 
be deferred during the COVID-19 pandemic if symptoms settle and in the absence of 
high-risk markers.12 In the absence of significant obstructive stenoses, different 
potential differential diagnoses should be considered, and further investigations and 
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treatments pursued as necessary (see below). A summary of this stepwise approach is 
provided in Fig. 3.  
Myocarditis is a well-recognised mimic of ACS and remains an important differential 
diagnosis in the COVID-19 pandemic. Other clinical manifestations ranging from 
asymptomatic presentations to cardiogenic shock have also been described in COVID-19 
patients with suspected myocarditis. Only few COVID-19 patients with a definitive 
diagnosis of myocarditis have so far been reported. In some of them, the presence of 
SARS-CoV-2 in myocardial biopsies has been described13, in others, no virus was 
observed, but inflammatory infiltrates were documented.14 During the recovery period, 
one month after the onset of COVID-19 symptoms, a patient presented with acute heart 
failure with a pattern of ischaemic reperfusion-injury pattern at biopsies. It seems, that 
myocarditis represents a heterogeneous condition in COVID-19 patients with different 
underlying mechanisms to explain the myocardial injury and consequently different 
conceptual therapeutic approaches: ranging from antiviral therapy to anti-inflammatory 
treatment. In this context, the role of cardiac imaging in guiding management may be 
limited (most of the patients have also multiple organ damage, which deserves global 
treatment)15 , although there still remains an important role in diagnosis and the 
evaluation and monitoring of myocardial function. Echocardiography is the first line 
imaging test, that may demonstrate myocardial thickening, wall motion abnormalities 
and a pericardial effusion, however confirmation may require further imaging. In order 
to identify myocarditis, some have proposed to use a late iodine enhancement or 
extracellular mapping with CCT to complement CCT angiography (exclusion of CAD).23 
The best test for myocarditis is however cardiac magnetic resonance (CMR) if practical 
to perform. It may show diffuse myocardial oedema causing pseudo wall hypertrophy, 
non-infarct patterns of late gadolinium enhancement, and increased signal on short T1 
inversion recovery (STIR), T1 mapping and T2 mapping sequences.24 Pericarditis can 
also present in COVID-19 patients. Diagnosis should be based on the classic criteria for 
acute pericarditis16, the exclusion of CAD, and it should be treated as such if the 
diagnosis is confirmed. 
 
Myocardial infarction with non-obstructive coronary arteries (MINOCA) is also a 
possible diagnosis17and seems to be more frequent in COVID-19.18 In these patients this 
may be due to rupture of a non-obstructive plaque or embolus. Continuous ECG 
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monitoring is recommended in such patients taking into account the higher risk for 
potential life threatening arrhythmias. Takotsubo or stress cardiomyopathy is reported 
in COVID-19, associated with a variable degree of ventricular dysfunction. In patients 
where this is suspected, repeat echocardiography after several weeks to confirm 
recovery of function should be planned. 
 
CMR is well placed to differentiate myocardial infarction, myocarditis and stress 
cardiomyopathy and should be considered in patients that are well enough to be 
scanned and in whom establishing a clear diagnosis is of clinical importance. However, 
CMR protocols should be  shortened to focus on addressing the key clinical questions 
and to avoid long acquisition times that may be challenging for COVID-19 patients. It is 
acknowledged that not all hospitals treating COVID-19 patients will have easy access to 
a dedicated CMR service without prolonged transport and in such circumstances CMR 
may be indicated but not practical.  
 
COVID-19 patients with thoracic pain and elevation of troponin due to pulmonary 
embolism are common. Due to inflammation, a high thrombogenicity is observed in this 
population, with a frequent concomitant elevation of D-dimer levels. A thoracic 
computed tomography (CT) should be performed in case of high suspicion, especially in 
patients with an unexplained aggravation of the dyspnoea and/or a desaturation. Silent 
deep venous thrombosis should also be assessed by venous Doppler. 
 
Finally, chest CT (ideally ECG-gated) can be used to investigate other causes of thoracic 
pain, like acute aortic syndromes, that will still present during the COVID-19 pandemic. 
Although transoesophageal echocardiography is an alternative for these patients 
especially if they are critically ill patients or cannot be transported for other reasons, its 
use should be restricted, given that it is an aerosol generating procedure. TOE might also  
be indicated in very rare cases of ACS when ventricular septal rupture or papillary 
muscle rupture are suspected and not well assessed by transthoracic echocardiography 
or computed tomography, before emergent surgery, irrespective of COVID-19 status. 
 
3.2 Suspicion of heart failure 
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In COVID-19 patients with potential myocardial injury, symptoms compatible with heart 
failure are quite challenging to elicit. Dyspnoea is frequent and may be associated with 
the need for oxygen support. Its origin may be due to the evolution of lung pathology or 
to the presence of associated myocardial dysfunction. Systemic Capillary Leak Syndrome 
(SCLS) is a paroxysmal permeability disorder that leads to an abrupt massive shift of 
fluids and proteins from the intravascular to the interstitial compartment. In some cases 
of COVID-19, tissue oedema may involve the myocardium and can induce transient 
myocardial dysfunction, potentially contributing to the pathogenesis of shock.19,20 An 
increase in myocardial extracellular volume detected using CMR T1 and T2 mapping 
techniques may serve as a diagnostic marker of SCLS in COVID-19 patients, although as 
mentioned the logistics of CMR scanning need to be carefully considered.21 Pulmonary 
embolism is quite frequent and may be difficult to diagnose given that in many patients 
D-dimer is increased in association with systemic inflammation. 
 
In symptomatic patients with high troponin and simultaneous high BNP/ NT-proBNP, 
the diagnosis of heart failure is likely and should be established with a bedside 
echocardiogram. In case of low BNP/ NT-proBNP, the likelihood of myocardial 
dysfunction related to myocardial injury is very low and echocardiography should not 
be performed systematically. Lung echography can also be very helpful in distinguishing 
between lung and cardiac pathology and can be rapidly performed at the bedside.22 In 
this setting of COVID-19 with high troponin, patients presenting with shock, signs of 
acute heart failure, suspicion of right ventricular dysfunction, haemodynamic instability 
without clear explanation, and cardiac murmur, bedside echocardiography is also 
indicated. It is clearly helpful for the evaluation of myocardial function, the detection of 
regional wall contraction abnormalities, acute valvular disease and for non-invasive 
haemodynamic assessments. The role of strain imaging is extremely limited due to the 
moderate quality of echocardiography imaging in these patients and the absence of ECG 
recordings in most of them. Pulmonary embolism should be excluded in case of 
unexplained right ventricular dysfunction or pulmonary hypertension as indicated in 
the section on chest pain. 
 
 
3.3 The patient with arrhythmias or syncope 
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In COVID-19 patients with myocardial injury, the occurrence of ventricular arrhythmias 
or syncope requires the exclusion of myocarditis, acute coronary syndromes, advanced 
valve disease, underlying cardiomyopathies or ventricular dysfunction. The latter may 
occur secondary to acute (i.e. hydroxychloroquine) or chronic medical treatments (i.e. 
anthracyclines in oncologic patients). Bedside echocardiography is the first line 
examination, with CMR and CT performed as required and appropriate as discussed 
above.  
 
3.4 The asymptomatic patient 
 
In COVID-19, pneumonia often predominates, and cardiac symptoms may be missed or 
absent. Critically ill intubated patients have usually not the opportunity to complain. 
However, routine cardiac imaging is not indicated. In patients with elevated troponins 
and myocardial injury, imaging may be considered but should not be routinely be 
performed if the ECG is not suggestive of CAD/cardiomyopathy/myocarditis and if the 
patient is haemodynamically stable. In some rare patients with a previous CVD history, 
echocardiographic assessments of myocardial function, can help risk stratify patients, 
and provide guidance for triage. 
 
3.5 Late follow-up 
In all hospitalized patients with myocardial injury that are finally discharged, careful 
follow-up encompassing cardiac imaging should be systematically offered to evaluate 
for residual cardiac damage and dysfunction. Lessons learnt from previous influenza 
pandemics are that CVD is a major source of complications post-infection25. Follow-up of 




A key message from the recommendations for cardiovascular imaging in COVID-19 was 
the need to avoid unnecessary cardiac imaging examinations in order to reduce 
transmission of the virus, protect health care professionals and conserve PPE. In COVID-
19 hospitalized patients, myocardial injury represents a frequent request for cardiac 
imaging, partly because it is known to convey a worse prognosis. The present paper 
aims to provide guidance to clinicians regarding the appropriateness of cardiac imaging 
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modalities in these patients, and how best to decipher the mechanism of myocardial 
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Table 1: Role of cardiac imaging modalities in COVID-19 patients with myocardial injury 
 
The degree of suspicion is related to the timing in the course of COVID-19, the profile of 
troponin elevation, symptoms, signs and ECG changes (see text for details). CAD= 
coronary artery disease, HF= heart failure, LE= lung embolism, SOE= source of 
embolism, CCTA: cardiac computed tomography angiography, CTT= Thoracic computed 
tomography, CMR= cardiac magnetic resonance, IE=infective endocarditis 
 
 
High troponin Echocardiography Lung ultrasound CCTA CTT CMR Invasive angio+ ventriculo 
Suspected CAD       
- Very low probability − − − − − − 
- Intermediate probability + − ++ − 
+ 
− 
















Ventricular arrhythmias ++ − + − + − 
Suspected myocarditis ++ − − − 
++ 
− 
Suspected pericarditis ++ − − + 
+ 
− 
Suspected LE + − − ++* − − 
Suspected SOE ++ − − + − − 






Table 2 Recognized associations with troponin elevation 
 
• Myocardial infarction (MINOCA) 
• Heterophile antibodies, such as in rheumatoid arthritis (troponin I) 
• Renal impairment (troponin T) 
• Congestive heart failure (severe) 
• Aortic stenosis 
• Aortic dissection 
• Severe pulmonary hypertension 
• Pulmonary embolism 
• Tachycardia with haemodynamic compromise 
• Direct injury to the heart (accidental trauma, ablation, cardiac surgery) 
• Toxins (e.g. adriamycin, 5-fluorouracil) 
• Percutaneous coronary intervention 
• Myocarditis, pericarditis, infective endocarditis 
• Cerebrovascular accident 
• Sepsis, critical illness 
• Extensive burns 
• Stroke, subarachnoidal haemorrhage 






















Figure 1: Indications for cardiac imaging in COVID-19 patients with myocardial injury 
CAD= coronary artery disease, VES= ventricular extrasystoles, HF= heart failure, VHD= 
valvular heart disease, LE= lung embolism, ICU= intensive care unit, SOE= source of 
embolism 
 
Figure 2: Additional possible mechanisms to classical coronary syndromes in COVID-19 
with myocardial injury 
 
 
Figure 3: Stepwise approach in COVID-19 with myocardial injury and suspicion of CAD 
QOL= quality of life, Tx= treatment, PTP= pre-test probability, CVD= cardiovascular 
disease, CVRF= cardiovascular risk factors, CCTA: cardiac computed tomography 
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